Preliminary evaluation of a nanotechnology-based approach for the more effective diagnosis of colon cancers

Nanomedicine

Volumn 5, Issue 9, 2010, Pages 1467-1479

  Lue, Niyom ^a   Ganta, Srinivas ^b   Hammer, Daniel X ^a   Mujat, Mircea ^a   Stevens, Amy E ^a   Harrison, Laurie ^a   Ferguson, R Daniel ^a   Rosen, David ^a   Amiji, Mansoor ^b   Iftimia, Nicusor ^a  

^a PHYSICAL SCIENCES INC   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

Author keywords

v 3 integrin receptor; arginine glycine aspartic acid; colon cancer; fluorescence imaging; functionalized polycaprolactone microparticle; gold nanoparticle; optical coherence tomography

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; COLLOIDAL GOLD; INTEGRIN; POLYCAPROLACTONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER DIAGNOSIS; CANCER SCREENING; CANCER TISSUE; COLON CANCER; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; FIBROBLAST; FLUORESCENCE IMAGING; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NANOTECHNOLOGY; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL;

ADENOCARCINOMA; ANIMALS; CELL LINE, TUMOR; COLON; COLONIC NEOPLASMS; CONTRAST MEDIA; FEMALE; GOLD; HUMANS; METAL NANOPARTICLES; MICE; MICE, NUDE; NANOTECHNOLOGY; OLIGOPEPTIDES;

EID: 78650039534     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/nnm.10.93     Document Type: Article

References (42)

1. Desch CE, Benson AB 3rd, Somerfeld MR et al.: Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J. Clin. Oncol. 23(33), 8512-8519 (2005).
2. Cappell MS: Pathophysiology, clinical presentation, and management of colon cancer. Gastroenterol. Clin. North Am. 37(1), 1-24 (2008).
3. Ott JJ, Ullrich A, Miller AB: The importance of early symptom recognition in the context of early detection and cancer survival. Eur. J. Cancer 45(16), 2743-2748 (2009).
4. Westcott EDA, Windsor ACJ: Can we improve the outcome of colorectal cancer by early diagnosis? Postgrad. Med. J. 78(919), 255-256 (2002).
5. Mandel JS, Church TR, Ederer F, Bond JH: Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J. Natl Cancer Inst. 91(5), 434-437 (1999).
6. Burch JA, Soares-Weiser K, St John DJ et al.: Diagnostic accuracy of fecal occult blood tests used in screening for colorectal cancer: a systematic review. J. Med. Screen. 14(3), 132-137 (2007).
7. Ouyang DL, Chen JJ, Getzenberg RH, Schoen RE: Noninvasive testing for colorectal cancer: a review. Am. J. Gastroenterol. 100(6), 1393-1403 (2005).
8. Johnson CD, Chen MH, Toledano AY et al.: Accuracy of CT colonography for detection of large adenomas and cancers. N. Engl. J. Med. 359(12), 1207-1217 (2008).
9. Sasajima K, Kudo SE, Inoue H et al.: Real-time in vivo virtual histology of colorectal lesions when using the endocytoscopy system. Gastrointest. Endosc. 63(7), 1010-1017 (2006).
10. Smith LA, Tiffn N, Thomson M, Cross SS, Hurlstone DP: Chromoscopic endomicroscopy: in vivo cellular resolution imaging of the colorectum. J. Gastroenterol. Hepatol. 23(7), 1009-1023 (2008).
11. Bouma BE, Tearney GJ, Compton CC, Nishioka NS: High-resolution imaging of the human esophagus and stomach in vivo using optical coherence tomography. Gastrointest. Endosc. 51(4), 464-474 (2000).
12. Testoni PA and Mangiavillano B: Optical coherence tomography in detection of dysplasia and cancer of the gastrointestinal tract and bilio-pancreatic ductal system. World J. Gastroenterol. 14(42), 6444-6452 (2008).
13. Hariri LP, Tumlinson AR, Wade NH et al.: Ex vivo optical coherence tomography and laser-induced fuorescence spectroscopy imaging of murine gastrointestinal tract. Comp. Med. 57(2), 175-185 (2007).
14. Tumlinson AR, Hariri LP, Utzinger U, Barton JK: Miniature endoscope for simultaneous optical coherence tomography and laser-induced fuorescence measurement. Appl. Opt. 43(1), 113-121 (2004).
15. Schmidbauer J, Remzi M, Klatte T et al.: Fluorescence cystoscopy with high-resolution optical coherence tomography imaging as an adjunct reduces false-positive fndings in the diagnosis of urothelial carcinoma of the bladder. Eur. Urol. 56(6), 914-919 (2009).
16. Luker GD, Luker KE: Optical imaging: current applications and future directions. J. Nucl. Med. 49(1), 1-4 (2008).
17. Miller J: Clinical molecular imaging. J. Am. Coll. Radiol. 1(1), 4-23 (2004).
18. Ntziachristos V, Bremer C, Weissleder R: Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging. Eur. Radiol. 13(1), 195-208 (2003).
19. Tung CH, Lin Y, Moon WK, Weissleder R: A receptor-targeted near-infrared fuorescence probe for in vivo tumor imaging. Chem. Bio. Chem. 3(8), 784-786 (2002).
20. Nakayama A, del Monte F, Hajjar RJ, Frangioni JV: Functional near-infrared fuorescence imaging for cardiac surgery and targeted gene therapy. Mol. Imaging 1, 365-377 (2002).
21. Yuan S, Roney CA, Wierwille J et al.: Co-registered optical coherence tomography and fuorescence molecular imaging for simultaneous morphological and molecular imaging. Phys. Med. Biol. 55(1), 191-206 (2010).
22. 3 in brain tumor xenografts. Cancer Res. 64(21), 8009-8014 (2004).
23. 3 in human tumor xenografts. Mol. Imaging 3(4), 343-351 (2004).
24. Ye Y, Bloch S, Xu B, Achilefu S: Design, synthesis, and evaluation of near infrared fuorescent multimeric RGD peptides for targeting tumors. J. Med. Chem. 49(7), 2268-2275 (2006).
25. Ebert EC: Mechanisms of colon cancer binding to substratum and cells. Gastrointest. Oncol. 41(8), 1551-1556 (2005).
26. Del Buono R, Pignatelli M, Bodmer WF, Wright NA: The role of the arginine-glycine-aspartic acid-directed cellular binding to type I collagen and rat mesenchymal cells in colorectal tumour differentiation. Differentiation 46(2), 97-103 (2006).
27. 3 antagonist, S-247, induces tumor regression and inhibits hypercalcemia of malignancy in a syngeneic mouse colon model. Proc. Am. Assoc. Cancer Res. 42, 825 (2001).
28. 3 integrin antagonists in orthotopic and experimental models. Proc. Am. Assoc. Cancer Res. 42, 263 (2001).
29. Lee TM, Toublan FJ, Sitafalwalla S et al.: Engineered microsphere contrast agents for optical coherence tomography. Opt. Lett. 28(17), 1546-1548 (2003).
30. Iftimia N, Mujat M, Ustun T, Ferguson D, Vu D, Hammer DX: Spectral-domain low coherence interferometry/optical coherence tomography system for fne needle breast biopsy guidance. Rev. Sci. Instrum. 80(2), 024302 (2009).
31. Chiang HS, Peng HC, Huang TF: Characterization of integrin expression and regulation on SW-480 human colon adenocarcinoma cells and the effect of rhodostomin on basal and upregulated tumor cell adhesion. Biochim. Biophys. Acta 1224(3), 506-516 (1994).
32. Koretz K, Brüderlein S, Henne C, Fietz T, Laqué M, Möller P: Comparative evaluation of integrin a-and b-chain expression in colorectal carcinoma cell lines and in their tumours of origin. Virchows Arch. 425(3), 229-236 (1994).
33. 2 integrin in fbroblasts isolated from cyclosporin A-induced gingival overgrowth in rats. J. Periodontal Res. 38(5), 533-537 (2003).
34. Shiraha H, Gupta K, Drabik K, Wells A: Aging fbroblasts present reduced epidermal growth factor (EGF) responsiveness due to preferential loss of EGF receptors. J. Biol. Chem. 275, 19343-19351 (2000).
35. Zysk AM, Boppart SA: Computational methods for ana lysis of human breast tumor tissue in optical coherence tomography images. J. Biomed. Opt. 11(5), 4015 (2006).
36. Mujat M, Ferguson RD, Hammer DX, Gittins C, Iftimia N: Automated algorithm for breast tissue differentiation in optical coherence tomography. J. Biomed. Opt. 14(3), 034040 (2009).
37. Agrawal A, Huang S, Lin AWH et al.: Quantitative evaluation of optical coherence tomography signal enhancement with gold nanoshells. J. Biomed. Opt. 11(4), 041121 (2006).
38. Boppart SA, Oldenburg AL, Xu C, Marks DL: Optical probes and techniques for molecular contrast enhancement in coherence imaging. J. Biomed. Opt. 10(4), 41208 (2005).
39. Kah JC, Olivo M, Chow TH et al.: Control of optical contrast using gold nanoshells for optical coherence tomography imaging of mouse xenograft tumor model in vivo. J. Biomed. Opt. 14(5), 054015 (2009).
40. Oldenburg AL, Hansen MN, Zweifel DA, Wei A, Boppart SA: Plasmon-resonant gold nanorods as low backscattering albedo contrast agents for optical coherence tomography. Opt. Express. 14(15), 6724-6738 (2006).
41. Cang H, Sun T, Li ZY et al.: Gold nanocages as contrast agents for spectroscopic optical coherence tomography. Opt. Lett. 30(22), 3048-3050 (2005). (Pubitemid 41655030)
42. Xu C, Ye J, Marks DL, Boppart SA: Near-infrared dyes as contrast-enhancing agents for spectroscopic optical coherence tomography. Opt. Lett. 29(14), 1647-1649 (2004).